Curcumin nanoformulations: a future nanomedicine for cancer.

Cancer Biology Research Center, Sanford Research/University of South Dakota, 2301 E. 60th Street North, Sioux Falls, SD 57104, USA.
Drug discovery today (Impact Factor: 5.96). 09/2011; 17(1-2):71-80. DOI: 10.1016/j.drudis.2011.09.009
Source: PubMed

ABSTRACT Curcumin, a natural diphenolic compound derived from turmeric Curcuma longa, has proven to be a modulator of intracellular signaling pathways that control cancer cell growth, inflammation, invasion and apoptosis, revealing its anticancer potential. In this review, we focus on the design and development of nanoparticles, self-assemblies, nanogels, liposomes and complex fabrication for sustained and efficient curcumin delivery. We also discuss the anticancer applications and clinical benefits of nanocurcumin formulations. Only a few novel multifunctional and composite nanosystem strategies offer simultaneous therapy as well as imaging characteristics. We also summarize the challenges to developing curcumin delivery platforms and up-to-date solutions for improving curcumin bioavailability and anticancer potential for therapy.

  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Solid lipid nanoparticles incorporating Curcuma longa L., Zingiberaceae, curcuminoids were produced by the hot melt emulsion method. A Box–Behnken factorial design was adopted to study the nanoparticles production at different levels of factors such as the percentage of curcuminoids, time of homogenization and surfactant ratio. The optimized nanoparticles were incorporated into hydrogels for stability, drug release and skin permeation tests. The average nanoparticle sizes were 210.4 nm; the zeta potential of −30.40 ± 4.16; the polydispersivity was 0.222 ± 0.125. The average encapsulation efficiency of curcumin and curcuminoids was 52.92 ± 5.41% and 48.39 ± 6.62%, respectively. Solid lipid nanocapsules were obtained with curcumin load varying from 14.2 to 33.6% and total curcuminoids load as high as 47.7%. The topical formulation showed good spreadability and stability when subjected to mechanical stress test remained with characteristic color, showed no phase separation and no significant change in pH. As a result of slow release, the nanoparticles were able to avoid permeation or penetration in the pig ear epidermis/dermis during 18 h. The topical formulation is stable and can be used in further in vivo studies for the treatment of inflammatory reactions, in special for radiodermitis.
    Revista Brasileira de Farmacognosia 02/2015; 1. DOI:10.1016/j.bjp.2014.11.010 · 0.80 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: New biocompatible nanomaterials are leading to a range of emerging health treatments. Thus, peptide drugs present in oral diseases, such as caries, periodontal diseases and oral cancer, are highlighting into clinical practice because the peptides can have an influence the growth of tumor cells or microorganisms and its can exhibit direct cytotoxic activity towards cancer cells or microbial cells. Therefore, it is interesting to speculate what are the natural or synthetic peptides that can be used to develop novel strategies to fight cancer diseases or microbial cells, and so, to represent a novel family of anticancer or antimicrobial agents. The use of buccal drug delivery systems, especially nanoparticles, to carrier peptides shows to be very interesting, because these systems can protect the peptide against enzymatic degradation, in addition to target inaccessible sites. However, this peptide delivery system seems to be unexplored by researchers. On the hand, the application of drug delivery systems for oral diseases could be a proposed treatment for these diseases, including the treatment or co-treatment with other therapies, such as photodynamic therapy, of antimicrobial, periodontal diseases and cancer, or even in the early diagnosis of cancer. The objective of this study is to present a systematic review of nanotechnology-based peptides delivery systems intended to oral diseases.
    Current Topics in Medicinal Chemistry 02/2015; 15(4):345-355. DOI:10.2174/1568026615666150108125040 · 3.45 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The delivery of significant concentrations of biologically active free curcuminoids (curcumin, demethoxycurcumin and bisdemethoxycurcumin) at the target tissues has always been regarded as a major limitation for the efficacy of curcumin. Herein we report the blood–brain-barrier permeability, tissue distribution and enhanced bioavailability of free curcuminoids following the oral administration of a food grade curcumin formulation in comparison with the standardized native curcumin, for the first time. UPLC-ESI-MS/MS analyses of post-administration tissue samples of Wistar rats (200 mg/kg body weight) demonstrated significant (p < 0.001) enhancement in plasma bioavailability (25-fold), in vivo stability and blood–brain-barrier permeability as evidenced from the tissue distribution of free curcuminoids at, (ng/g), brain (343 ± 64.7), heart (391.7 ± 102.5), liver (445.52 ± 83), kidney (240.1 ± 47.2), and spleen (229.72 ± 42.2), with extended elimination half-life of 3 to 4 h. Standard curcumin, on the other hand, detected only 1.4 ± 0.8 ng/g of curcumin in the brain tissues.
    Journal of Functional Foods 04/2015; 14. DOI:10.1016/j.jff.2015.01.049 · 4.48 Impact Factor


Available from